Class summary at a glance.

Every drug in the Cytochrome P450 3A Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 8tracked in Part D
CY24 Part D spend: $9.8Mcombined across class
Total Rx claims: 75K13K unique beneficiaries
Generic mfrs (active): 10across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Ritonavir

Brand: Norvir · 74K Part D claims (CY24) · 12K beneficiaries · First FDA approval: 2017-06-07

5 generic mfrs 0 plans require PA

Low NADAC$0.652

→

Avg plan cost$1.93

Part D spend $9.4M 3× spread, current vs floor

Class share

96%

of class CY24 spend

View profile →

Cobicistat

Brand: Tybost · 1K Part D claims (CY24) · 238 beneficiaries · First FDA approval: 2014-09-24

Brand-only (no generics) 0 plans require PA Discontinued

Low NADAC—

→

Avg plan cost—

Part D spend $391226

Class share

of class CY24 spend

View profile →

Atazanavir and Cobicistat

Brand: EVOTAZ · — Part D claims (CY24) · First FDA approval: 2015-01-29

Brand-only (no generics) 0 plans require PA Discontinued

Low NADAC$51.98

→

Avg plan cost$51.98

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Darunavir Ethanolate and Cobicistat

Brand: PREZCOBIX · — Part D claims (CY24) · First FDA approval: 2015-01-31

Brand-only (no generics) 0 plans require PA

Low NADAC$79.99

→

Avg plan cost$79.99

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide

Brand: Symtuza · — Part D claims (CY24) · First FDA approval: 2018-07-17

Brand-only (no generics) 0 plans require PA

Low NADAC$152.95

→

Avg plan cost$152.95

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide

Brand: Genvoya · — Part D claims (CY24) · First FDA approval: 2015-11-05

Brand-only (no generics) 0 plans require PA

Low NADAC$143.35

→

Avg plan cost$143.35

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil

Brand: Stribild · — Part D claims (CY24) · First FDA approval: 2012-08-27

Brand-only (no generics) 0 plans require PA

Low NADAC$150.41

→

Avg plan cost$150.41

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Lopinavir and Ritonavir

Brand: Kaletra · — Part D claims (CY24) · First FDA approval: 2010-06-18

5 generic mfrs 0 plans require PA

Low NADAC$4.70

→

Avg plan cost$4.70

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.